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INTRODUCTION
Multiple myeloma (MM) is a plasma
cell (PC) neoplasm that leads to renal
failure, hypercalcemia and skeletal de-
struction resulting in a median length of
survival at diagnosis of approximately
3–5 years (1). There are thought to be
three general categories of factors that
promote the growth and/or survival of
MM cells in vivo (2,3). The first consists
of factors such as interleukin 6 (IL-6),
IL-10 and interferon-α that trigger
JAK/STAT (janus kinase/signal trans-
ducer and activator of transcription)
pathways, which can lead to activation
of mitogen-activated protein (MAP) ki-
nases that drive cell proliferation. In ad-
dition, insulinlike growth factor (IGF)-1,
HGF (hepatocyte growth factor) and
EGF (epidermal growth factor) family
members that engage syndecan-1 are
known to activate not only proliferative
pathways via the MAP kinases, but also
survival pathways via activation of the
phosphatidylinositol 3-kinase (PI3K)/
Akt/mammalian target of rapamycin
(mTOR) pathway. The third pathway
 involves the B-lineage–specific BAFF
(B-cell activating factor) and April recep-
tors, whose ligands can trigger activa-
tion of PI3K/Akt and nuclear factor
κ-light-chain-enhancer of activated
B cells (NF-κB) activities that promote
cell survival.
High-throughput analysis systems
have defined the transcriptome and pro-
teome of MM and other tumor cells
(4–6). Novel insights in the MM tran-
scriptome have led to the notion that the
majority of transcripts are necessary to
keep a cell functioning and could be re-
garded as the minimal transcriptome.
Only a small portion of the transcripts
present in the cell determine the identity
of the cell, and these critical transcripts
are normally expressed at low levels.
Therefore small changes in the expres-
sion profiles in this part of the transcrip-
tome can lead to large changes in the en-
zymatic profile of the cell, leading to
significant differences in cell functioning
(7). Hence, an equally, if not more impor-
tant, goal is to define the activity of the
proteins that control the status of signal-
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ing pathways available in experimental
models (8). Kinases, the enzymes that
phosphorylate tyrosine, serine and threo-
nine residues on other proteins, play a
major role in controlling the status of sig-
naling cascades that determine, for ex-
ample, cell cycle entry and survival.
Knowing the status of signaling path-
ways in MM cells and their supporting
stroma could provide critical information
for understanding MM cell survival in
the bone marrow (BM). Thus, a compre-
hensive description of cellular metabo-
lism could be a valuable complement to
descriptions of the proteome and tran-
scriptome. We have developed a novel
array-based strategy that allows the si-
multaneous detection of enzymatic activ-
ities for the phosphorylation of different
kinase substrates in one cell sample
(9–11). Here we apply this technology to
primary MM isolates to assess the differ-
ences in kinase activity between MM
cells and their normal PC counterparts,
in addition to stromal elements that may
also have an impact on MM growth and
survival. These large-scale kinome com-
parisons reveal multiple, deregulated
signaling pathways in MM and the sur-
rounding BM blood cells and reveal po-
tential novel avenues for therapy in this
deadly blood cell cancer.
MATERIALS AND METHODS
Patient Samples
For cell sorting, MM primary patient
samples were obtained from the liquid
tissue acquisition core at H. Lee Moffitt
Cancer Center. Mononuclear cells were
collected by the tissue acquisition staff
via Ficoll-gradient centrifugation. For
normal PC sorts and phosphoflow, nor-
mal human BM samples were received
as mononuclear cell suspensions in
 Hanks’ balanced salt solution with
5 mmol/L EDTA and 0.5% bovine
serum albumin (1M-125; Lonza-Poietics,
Basel, Switzerland). For phosphoflow
analysis, non-MM and MM samples
were obtained from the Frozen Liquids
Tissue Core at H. Lee Moffitt Cancer
Center.
Fluorescence-Activated Cell Sorting
The populations of interest were sorted
from both the MM and the normal human
BM mononuclear cells in the same man-
ner. The Fc receptors were blocked with
anti–human CD32, and the sample was
stained with anti–human CD38–fluorescein
isothiocyanate (FITC), anti–human
CD138-phycoerythrin (PE) and DAPI 
(4′6-diamidino-2-phenylindole·2HCl). The
CD38hiCD138+ and CD38–CD138– popula-
tions were collected separately by use of
fluorescence- activated cell sorting (FACS)
with an FACSAria (BD, Franklin Lakes,
NJ, USA).
FACS Analysis
Cell surface marker expression on non-
PC was analyzed by staining BM
mononuclear cell fractions with the fol-
lowing antibodies: CD45-FITC, CD19-
FITC, CD34-FITC, CD3-FITC, CD41a-
APC, CD14-FITC, CD71-FITC, CD33-
FITC, CD138-FITC, CD11b-FITC, CD36-
FITC, VCAM-FITC (CD106) or glyco -
phorin A (GPA)-PE. To exclude PC and
dead cells, samples were simultaneously
stained for CD38-PE or CD38-FITC and
DAPI.
Phosphoflow
The phosphoflow monoclonal anti-
body anti-ERK1/2(pT202/pY204), conju-
gated to Alexa Fluor 647, was purchased
from BD Pharmingen (San Diego, CA,
USA). Cells were stained with CD38,
CD138 and p-ERK, or the appropriate
isotype control according to the manu-
facturer’s protocol for phosphoflow anal-




Each of the MM or normal BM (NBM)
isolates prepared were applied to a 
Pep Chip slide. The PepChip used for
profiling is the kinase v1 version contain-
ing duplicates of 1176 spots (1152 plus 24
control spots) derived from the annotated
PhosphoBase (version 2.0) (57). Informa-
tion on phosphorylation sites can be ob-
tained through http://www.hprd. org/.
For the array samples, 0.5 × 106 cells were
lysed in cell lysis buffer (20 mmol/L Tris-
HCl, pH 7.5, 150 mmol/L NaCl,
1 mmol/L Na2EDTA, 1 mmol/L EGTA,
1% Triton X-100, 2.5 mmol/L sodium py-
rophosphate, 1 mmol/L MgCl2, 1 mmol/L
beta- glycerophosphate, 1 mmol/L
Na3VO4, 1 mmol/L NaF, 1 μg/mL leu-
peptin, 1 μg/mL aprotinin, 1 mmol/L
phenylmethylsulfonyl fluoride), and de-
bris was removed by centrifugation. The
peptide array incubation mix was pro-
duced by adding 10 μL of filter-cleared
activation mix (50% glycerol, 50 μmol/L
ATP, 0.05% v/v Brij-35, 0.25 mg/mL
bovine serum albumin) and 2 μL [γ-33P]
ATP (approximately 1000 kBq; Amer-
sham AH9968, Amersham Biosciences,
Piscataway, NJ, USA) Next, the peptide
array mix was added onto the chip, and
the chip was kept at 37°C in a humidified
incubator for 90 min. Subsequently the
peptide array was washed twice with
Tris-buffered saline with Tween 20, twice
in 2 mol/L NaCl, and twice in demineral-
ized H2O, and then air-dried. The chips
were exposed to a phosphoimager plate
for 72 h, and the density of the spots was
measured and analyzed with array soft-
ware (ScanAnalyze).
Data Analysis
The 5% and 95% intervals of the spot
density were calculated for each data set,
and all spots were normalized within the
boundaries for which the 5% level equals
0 and 95% is given the value 100. If only
background phosphorylation is present,
this amplitude-based distribution can be
described by a single exponent. Because
at low intensities of phosphorylation the
contribution of biological phosphoryla-
tion is minimal, and hence the data in this
range contain almost exclusively pure
noise, we determined the exponent de-
scribing the amplitude behavior of the 250
least phosphorylated peptides, ranked
from lowest to highest intensities, to give
an adequate description of array back-
ground phosphorylation. True phospho-
rylation events were considered to have
occurred for peptides of which the aver-
age phosphorylation minus z times the
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SD was higher than the value expected
from describing the background distribu-
tion. For integrated pathway analysis, z
was a floating value designed to maxi-
mize difference between the kinomes; for
all other analyses z was set to 1.96, which
yielded a P value of 0.05 or better for each
“on” call made. The set of peptides that
thus showed statistically significant phos-
phorylation compared to the background
was then subjected to elective Markov
analysis, i.e., assuming that different pep-
tides acting as substrates for the same ki-
nase have different affinity for phospho-
rylation by this kinase, kinases more
active in one condition compared to an-
other condition should display in the
more active condition more phosphory-
lated target peptides. Thus the extent to
which a kinase activity can be determined
precisely is dependent on the number of
substrates for the kinase (hence analysis
for epidermal growth factor receptor
(EGFR), for which only 2 peptides are
present on the chip, is much more impre-
cise than analysis for protein kinase B, for
which >15 peptides are present).
Western Blot Analysis
Sorted cells were lysed in cell lysis
buffer as described above. Protein con-
centration was determined by bicin-
choninic acid protein assay (Pierce,
 Rockford, IL, USA) according to the man-
ufacturer’s instructions. Laemmli sample
buffer was added to the samples and
sodium dodecyl sulfate– polyacrylamide
gel electrophoresis (SDS-PAGE) and im-
munoblotting were performed as de-
scribed (58). Detection was performed ac-
cording to the manufacturer’s guidelines
(ECL, Pierce, Rockford, IL, USA). All
phosphoantibodies were from Cell Sig-
naling Technology (Beverly, MA, USA).
Membranes were reprobed with an anti-
body against actin (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and den-
sitometry of the blots was performed
using ImageMaster 1D Elite (Pharmacia,
Woerden, the Netherlands).
Cell Viability Assay
MM cell lines RPMI8226, U266 and
OPM2 were routinely maintained in
RPMI1640 (PAA Laboratories, Etobicoke,
Ontario, Canada) supplemented with
10% fetal calf serum (PAA Laboratories).
Cells were treated in duplicate for 36 h
with increasing concentrations of
sirolimus (LC Laboratories, Woburn,
MA, USA), U1026 (Cell Signaling Tech-
nology) or protein kinase G (PKG) in-
hibitor (Calbiochem, Merck, Darmstadt,
Germany). 3-(4,5-Dimethylthiazol-2-yl)-
2,5diphenyltetrazolium bromide (MTT)
(Sigma, St Louis, MO, USA) was added
at a concentration of 0.5 mg/mL to the
cells for 3 h. Formed crystals were dis-
solved in dimethyl sulfoxide and optical
density (OD) was measured at 570 nm.
The OD of compound treated cells was
divided by the OD of their vehicle con-
trol, and the viability was expressed as a
percentage of untreated cells. Results are
expressed as mean ± SEM of three indi-
vidual experiments.
All supplementary materials are available
online at www.molmed.org
RESULTS
Comparison of MM and NBM PC
Kinome
MM cells present in BM can be identi-
fied by the expression of high levels of
CD38 and CD138 (12). CD38hiCD138+
MM cells from BM aspirates were ob-
tained from 10 different patients and 10
different healthy BM donors with NBM
(see representative Bone Marrow Sort,
Supplementary Figure 1). We subse-
quently conducted a comparison of the
kinase activities present in MM cells to
those present in normal PC by applying
PepChip array technology on the iso-
lates. Figure 1A shows representative
Figure 1. Comparison of the MM cell and normal PC phosphoproteomes. (A) Phosphoim-
ager scans of “1152” spot PepChip™ for MM cells (red) and normal PC (green) from two
representative MM patients and two normal donors. (B) Scatter plot showing the mean
amount of phosphorylation detected by PepChip™ for all 1152 substrates in MM cells 
(y axis) versus normal PC (x axis). Each spot on the plot represents the mean phosphoryla-
tion across 10 different MM cell sorts (y axis) and 10 different normal PC sorts (x axis). Indi-
cated in the graph are the differently phosphorylated substrates Insulin receptor signaling
(green) and S6 Kinase (red). (C) Venn diagram of number of substrates receiving an “on”
call according to Markov analysis of the mean substrate phosphorylation of lysates from
10 MM patients and 10 normal donors.
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PepChip phosphorimager scans for puri-
fied MM and NBM PC from 2 of 10 dif-
ferent MM patients and 2 of 10 normal
donors. In Figure 1B we show an MM
versus a normal PC profile scatter plot in
which each dot represents the normal-
ized mean phosphorylation level for
each of the 1152 substrates arrayed in
duplicate on the PepChip for all MM cell
and normal PC samples analyzed. As ex-
pected there is a great deal of similarity
between the two kinomes; however,
there is also a distinct subset of sub-
strates that fall off the diagonal. Among
these are the p70S6K target ribosomal
protein S6 and the insulin receptor, the
phosphorylation of which was increased
in MM PC (Figure 1B). The insulin recep-
tor shares 60% homology with the IGF-1
receptor, and binding of IGF-1 leads to
its autophosphorylation and activation.
IGF-receptor signaling is one of the most
important growth, survival and migra-
tion signals for MM PC, and numerous
groups have reported autocrine IGF-1
production for primary MM cells and
myeloma cell lines (13,14).
Characterization of the Deregulated
Kinome in MM Plasma Cells
Next, the normalized values were sub-
jected to Markov analysis, which re-
sulted in the generation of an “on” or
“off” call for each kinase substrate, much
like what is generally done for gene ex-
pression profiling, representing phospho-
rylation events that were significantly
above background. To obtain a first in-
sight into the characteristics of the PC ki-
nome in general and the differences be-
tween the PC kinome and the MM
kinome in particular, we performed an
integrated pathway analysis using a
floating value of z (see Materials and
Methods) to maximize the contrast be-
tween the two datasets. The results are
presented in Supplementary Figure 2,
which depicts for the two cell types for
different kinases the fraction of kinase
substrates receiving an “on” call. These
results show that the differences between
the two kinomes are mainly localized to
the activation of the mTOR signaling
pathway and the MAP kinase pathway.
Subsequently, we fixed z to yield a
P value of 0.05 for each “on” call, which
diminishes contrast between the kinomes
but provides good confidence in state-
ments made. In total, 64 kinase sub-
strates received an “on” call in MM PC
versus 88 in NBM PC, with an overlap of
55 spots (see Supplemental Table S1 and
Figure 1C). The nine significantly phos-
phorylated substrates that are specific for
MM PC include cGMP-dependent pro-
tein kinase (PKG), cAMP response-
 binding element (CREB), histone H2A,
histone 1A and myosin light chain 2.
Upregulation of the mTOR-p70S6K-S6
and ERK1/2 Pathways in MM PC
In MM but not NBM PC, PepChip data
showed significant phosphorylation of
the Ser133 target sequence of CREB, a
known substrate for S6K and the MAPK
ERK1/2, suggesting an enhanced consti-
tutive activity of these pathways in MM
cells. To validate this in a method inde-
pendent of PepChip analysis, we sorted
CD38hiCD138+ cells from two new MM
patients and healthy donors, and com-
pared the phosphorylation (and hence
activation) status of the major molecules
in this pathway according to Western
blot analysis. Figures 2A and C show
that phosphorylation levels of mTOR,
p70S6K and S6 ribosomal protein, al-
Figure 2. Validation of PepChip analysis of MM and normal PC sorts. (A,B) Sorted CD38hi
CD138+ cells from MM patients or NBM donors were lysed and proteins were separated
by SDS-PAGE, after which the blots were probed with antibodies against phosphorylated
mTOR, p70S6K and S6 ribosomal protein (A) or phosphorylated IκB (B). Equal loading was
confirmed by reprobing the blots with antibodies against actin. (C) For quantification of
phosphorylated protein, densitometry values were divided by the densitometry values of
total actin protein present in the same samples. The values obtained for NBM patient
samples are represented as a percentage of densitometry values of MM samples. Mean
± SEM of data are shown. (D) (i) Gating strategy to identify MM cells in a representative
MM patient BM aspirate. MM cells were identified by the CD38hiCD138+ phenotype (red
polygon). (ii) Gating strategy to identify normal PC in a non-MM BM aspirate (green poly-
gon). (iii, iiii) Two individual experiments in which phospho-MAPK levels in CD38hiCD138+
MM plasma cells (red histogram) or CD38hiCD138+ normal PC (green histogram) and iso-
type-matched control stains for CD38hiCD138+ cells present in pooled MM and non-MM
BM aspirates (blue histogram). The mean fluorescence intensity (MFI) for the p-MAPK stains
and the isotype control stain are indicated in the upper right hand corner of each pair-
wise comparison of CD38hiCD138+ cells in MM and non-MM BM.
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though variable, as a mean were higher
in MM PC compared with those in their
normal counterparts.
To validate increased MAPK pathway
activity in MM cells, we examined the
level of MAPK phosphorylation in pri-
mary MM cells and normal PC by Phos-
phoFlow (Figure 2D). This analysis
showed increased phosphorylation, and
hence activity, of MAPK in MM cells
compared with normal PC in both pairs
of BM aspirates analyzed (Figure 2D, i,iii
and ii,iiii), consistent with our PepChip
findings.
Next, we performed functional analy-
sis of the dependence of MM cells on
mTOR and MEK-ERK pathways for sur-
vival. Inhibition of either of these path-
ways with a selective inhibitor (i.e.,
sirolimus and U0126, respectively) de-
creases numbers of viable cells in three
MM cell lines (Figure 3A, B). The data
shown in Figure 3D demonstrate that
treatment of MM cells with sirolimus
 inhibits constitutive and IGF-induced
phosphorylation of both p70S6k and S6,
but not ERK1/2. Vice versa, U0126 in-
hibits ERK1/2 phosphorylation, but not
that of the p70S6k-S6 pathway. Interest-
ingly, combined treatment at concentra-
tions that induce very little cell death in-
dividually inhibited phosphorylation of
both the P70S6K-S6 and ERK1/2 path-
ways, resulting in an additive effect on
cell viability (Figure 3C). These data cor-
roborate the notion that simultaneous in-
hibition of two independent survival
pathways (i.e., p70S6K and ERK1/2) may
be beneficial in the treatment of MM.
Phosphoproteome of Normal PC
The substrates that received an “on”
call in NBM PC, but not in MM PC, in-
cluded IL-1α, as well as the Src kinase
substrate focal adhesion kinase (FAK),
which activates the phosphorylation site
Tyr577, and Annexin II. In light of the
fact that PC from high-risk MM patients
have been described to express high lev-
els of IL-1β, this may seem surprising.
IL-1 is thought to stimulate para- and
 autocrine IL-6 production in MM (15,16),
and is a known physiological activator of
NF-κB in B-lymphoid cells (17). Activa-
tion of NF-κB through FAK has been re-
ported to play a role in IL-6 production
in myoblasts (18). In addition, Src activ-
ity has been linked to NF-κB activity in
mediating B-cell development (19). Acti-
vation of NF-κB requires its release from
inhibitory factors, inhibitors of κB (IκBs),
which are degraded upon phosphoryla-
tion by IκB kinases. We used Western
blot analysis to compare IκB phosphory-
lation in three MM patients with that in
to two healthy controls, and we observed
 variable phosphorylation of IκB, with a
higher mean densitometry in normal PC,
suggestive of NF-κB activation (Fig-
ure 3B, C).
Comparison of MM and NBM Non-PC
Kinomes
MM PC are known to influence their
BM microenvironment directly, by cy-
tokine production and stimulation of os-
teoclast activity, and indirectly, by physi-
cal reduction of BM space by MM PC ac-
cumulation, resulting in impaired resid-
ual hematopoiesis. Indeed, by FACS
analysis we observed significantly lower
percentages of T cells (CD3+), early
myeloid cells (CD33+) and granulocytic
cells (CD11b+) in MM BM (n = 7) com-
pared to normal BM (n = 6) (Supplemen-
tary Figure 3).
To determine whether there are signifi-
cant signaling differences between the
MM and normal BM microenvironment
cells, we also sorted non-PC from 10 MM
patients and 10 NBM donors (See Sup-
plementary Figure 1 for an example of
sorting and Figure 4A for representative
PepChip phosphorimager scans). This
fraction is enriched for cells from the ery-
throid lineage (CD36+, CD71+, GPA+)
(Supplemental Figure 3B). Figure 4B
shows a MM versus normal non-PC
phosphoproteome profile scatter plot, in-
dicating a high degree of similarity be-
tween these groups. Markov analysis re-
Figure 3. Additive cell killing by ERK and mTOR pathway inhibitors in MM cells. (A, B) MM
cell lines were treated for 48 h with increasing concentrations of sirolimus or U0126, after
which viable cell number was determined by MTT. Mean of 3 independent experiments is
shown. (C) MM cell lines were treated with 100 μmol/L sirolimus, 10 μmol/L U0126 or a
combination thereof. MTT assay was performed in three independent experiments and re-
sults represent the mean percentage survival rate of cells. (D) MM cells were treated with
100 μmol/L sirolimus (2 h), 10 μmol/L U0126 (30 min) or a combination thereof, after which
cells were lysed and proteins were separated by SDS-PAGE. Blots were probed with anti-
bodies against phosphorylated p70S6K, S6 ribosomal protein and ERK1/2. Equal loading
was confirmed by reprobing the blots with antibodies against actin. 
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sulted in an “on” call for 58 kinase sub-
strates in MM non-PC, compared to 102
in NBM samples, with an overlap of 55
substrates (Supplemental Table S2). An
“on” call was present for five vimentin-
specific substrates in NBM CD38–CD138–
cells, which were not present in MM
stromal cells, a result that is strongly
suggestive of a more adhesive phenotype
in normal stromal cells. Vimentin is
phosphorylated by active PAK2 kinase,
and an increased phosphorylation (and
hence activation) of PAK2 in CD38–
CD138– cell lysates from two individual
MM patients and two healthy BM donors
was confirmed by Western blot analysis
(Figure 5).
Whereas in PC, S6K and ERK signal-
ing were increased in MM samples, the
opposite was observed in non-PC sam-
ples. Two substrates for ERK1/2 kinase
activity and one for 6S-kinase were phos-
phorylated in NBM cells, but not MM
samples. In addition, phosphorylation of
eukaryotic translation and initiation fac-
tor 4F, a target of the mTOR/p70S6K
pathway, was also observed in normal
CD38–CD138– cells. Western blotting in-
deed showed an increased phosphoryla-
tion of mTOR, p70S6K and S6 in normal
stromal elements compared with MM
non-PC, a finding indicative of activation
of this pathway.
These results suggest widespread
downregulation in signaling in MM BM
cells, although the mixture of cell types
present makes it impossible to assign ki-
nase activity to individual populations
and speculate on the meaning for these
cell types. However, these results do
demonstrate that in addition to MM PC,
non-PC BM cells in general are also
deregulated in MM patients.
Common Targets in MM Plasma Cells
and MM Stromal Cells
In a final step we checked whether
there are common substrates that are af-
fected in both PC and stromal cells in
MM. Correlation analysis of mean phos-
phorylation of substrates shows a high
correlation between MM PC and NBM
PC (0.92), and between MM non-PC and
NBM non-PC (0.903). However, this high
degree of correlation was not observed
when PC and non-PC were compared in
MM patients (0.77) or NBM (0.79), sug-
gesting that PC have a kinome profile
that is distinct from the rest of the BM.
Per donor, correlations ranged from 0.667
to 0.89 for MM patients (mean 0.78 ±
0.072) and from 0.53 to 0.96 for NBM
donors (mean 0.80 ± 0.14). No overlap
was found between the substrates that re-
ceived an “on” call in MM PC but not
normal PC and those that were “on” in
MM non-PC versus NBM non-PC. In con-
trast, of the 33 spots more strongly phos-
phorylated in NBM CD38hiCD138+ PC
compared with MM PC, 25 (76%) were
also upregulated in NBM CD38–CD138–
non-PC compared with MM non-PC, in-
dicating common deregulation of these
pathways in both tumor and microenvi-
ronmental cells in MM BM. However,
whereas 33 kinase targets were more
phosphorylated in NBM PC, 102 spots
were specifically upregulated in non-PC
from healthy controls compared with
their MM counterparts. This large differ-
ence might be the result of the presence
of multiple individual cell types in the
CD38–CD138– fraction, all contributing to
the overall kinome profile. Of 189 target
sequences phosphorylated in all four
groups, i.e., PC and non-PC from MM
and NBM, 43 received an “on” call in all
of these. These sequences and the kinases
they represent are likely the minimal ki-
nome that is active in BM-derived cells.
DISCUSSION
We used the PepChip platform to de-
termine which signaling pathways are
deregulated in MM by directly compar-
ing purified cell populations prepared
from MM and normal BM isolates. We
successfully demonstrated that the phos-
phoproteome of MM cells is significantly
different from that of their normal PC
counterparts.
In MM PC, 64 kinase substrates were
phosphorylated versus 88 in normal PC.
Figure 4. Comparison of the microenvironment phosphoproteomes in MM BM and NBM.
(A) Representative phosphoimager scans of “1152” spot PepChip™ for CD38–CD138–
stroma cells from two different NBM donors (green) and two different MM BM patients as
indicated (red). (B) Scatter plot showing the mean level of phosphorylation for all 1152
substrates in MM CD38–CD138– cells (y axis) versus normal BM CD38–CD138– cells (x axis).
Each spot on the plot represents the mean phosphorylation across 10 different MM cell
sorts (y axis) and 10 different normal PC sorts (x axis). (C) Venn diagram of number of sub-
strates receiving an “on” call according to Markov analysis of the mean substrate phos-
phorylation of 10 MM patient and 10 normal donor non-PC lysates.
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In non-PC, 58 kinase substrates received
an “on” call in MM samples compared
with 157 in NBM. These numbers dem-
onstrate that kinase activity in general is
dramatically decreased in diseased cells
compared with normal cells. This result
is somewhat surprising, because many
studies have focused on inhibition of ac-
tive signaling pathways as a strategy for
treatment of this disease. However, most
studies have focused either on stimu-
lated kinase activity or on constitutive
activity as a secondary result of another
defect, such as deletion of the phos-
phatases PTEN (phosphatase and tensin
homolog) or CD45 (20,21), which is not
very common in MM (22). Our results
suggest that although some pathways
are highly constitutively activated in MM
cells, the remaining kinome profile is re-
pressed, a finding that may well reveal
fundamental aspects of the transformed
cells; the focus it has on proliferative
pathways can result in a downregulation
of other pathway activities, which are
normally important in untransformed
cells. In other words, the amount of en-
ergy available to a transformed cell may
be redistributed to lead to overactivation
of relatively few pathways, at a cost of
other cellular signaling pathways. Simi-
lar results were demonstrated in actute
myeloid leukemia (AML) cells, suggest-
ing that this phenomenon might be com-
mon in hematological malignancies 
(A ter Elst, personal communication).
One of the phosphorylated substrates
in MM PC was PKG, which has been
best described regarding its role in medi-
ating nitric oxide (NO) signaling (23).
Hypoxic factors such as NO are capable
inducers of angiogenesis, and NO signal-
ing through PKG has been linked to
 insulin-induced production of vascular
endothelial growth factor (VEGF-1) in
smooth muscle cells (24). This potent an-
giogenic factor is also secreted by MM
cells in response to IGF-1 stimulation,
and increased VEGF-1 serum levels are
correlated with poor prognosis in MM
patients (25,26). Interestingly, malignant
MM PC express high levels of nitrotyro-
sine, a marker of NO presence, and NO-
synthase 1, 2 and 3. In addition, serum
levels of NO are elevated in MM patients
(27,28). Interestingly, orally tolerable NO-
synthase inhibitors are available, and
were shown to have antiangiogenic ef-
fects in a MM mouse model, reducing
both tumor burden and VEGF produc-
tion by MM cells (29). In addition to a
role in angiogenesis, NO-activated PKG
has also been implicated in antiapoptotic
mechanisms in leukemic cells (30). We
now show that chemical inhibition of
PKG indeed reduces cell viability in
three different MM cell lines (Supple-
mentary Figure 4). Therefore, it is inter-
esting to speculate on a potential benefit
of NO-synthase or PKG inhibitors in the
treatment of MM.
Our data showed an “on” call for FAK,
Src kinase and IL-1α in normal PC, but
not MM PC, in conjunction with an in-
creased phosphorylation of IκB phospho-
rylation, suggestive of NF-κB activity.
However, several studies have shown
that NF-κB activation is present in MM
cells. Inhibitors of this pathway, such as
the proteasome inhibitor Bortezomib,
which inhibits NF-κB activity by pre-
venting degradation of IκB, have been
shown to be of clinical benefit in 35% of
patients (31). Our results might be ex-
plained by the fact that MM can be a het-
erogeneous disease, and in our analysis
we show only substrates that were as a
mean activated in 10 individual donors.
In other words, although individual MM
patients might present with increased
NF-κB activity, this might not show up in
a cross-examination of 10 patients. Fur-
thermore, proteasome inhibitors are most
effective when used in cotreatment strat-
egies (32,33). Recently it was reported
that NF-κB activity in MM cells was
 enhanced by conventional drugs like
melphalan and doxorubicin, and was
subsequently inhibited by proteasome
inhibitors like Bortezomib (34). Because
our MM samples were obtained at diag-
nosis, this might explain why we do not
find an enhanced IκB phosphorylation in
these patients.
Our analysis of the deregulated sub-
strates in MM PC showed increased
MAPK and mTOR/p70S6K pathway ac-
tivity. These changes, in combination
with other mutations, might be sufficient
to cause the MM cell to assume malig-
nant properties. Alternatively, early re-
Figure 5. Validation of PepChip analysis of MM and normal non-PC sorts. (A, B) Sorted
CD38–CD138– non-PC from MM patients or normal donors (NBM) were lysed and proteins
were separated by SDS-PAGE, after which the blots were probed with antibodies against
phosphorylated FAK, PAK2 and S6 ribosomal protein (A) or phosphorylated mTOR or
p70S6K (B). Equal loading was confirmed by reprobing the blots with antibodies against
actin. (C) For quantification of phosphorylated protein, densitometry values were divided
by the densitometry values of total actin protein present in the same samples. Results are
subsequently presented as percentage of corrected MM densitometry values. 
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ports suggested that apoptosis induction
in MM cells in response to therapeutic
agents like dexamethasone was a result
of downregulation by these agents of the
MAPK and p70S6K pathways (35). Later
studies indicated that inhibition of
mTOR by rapamycin-sensitized MM cell
lines and primary MM cells to dexam-
ethasone treatment (36), which was also
shown in an in vivo mouse model (37).
Our study results showing increased
(constitutive) phosphorylation of the
mTOR-p70S6K-S6 pathway in primary
MM PC, and the sensitivity of MM cells
to sirolimus, provide a rationale and in-
centive for the use of mTOR inhibitors in
the treatment of MM. Interestingly, phase
I/II clinical trials are currently being per-
formed with NVP-BEZ235, an orally
bioavailable compound that has been
shown to reduce mTOR activity and MM
proliferation (38). However, in addition
to mTOR, this drug also targets the PI3K
pathway. Given that our PepChip analy-
sis did not reveal a major deregulation of
this pathway in an average of 10 MM pa-
tients, more specific inhibitors, targeting
only mTOR and its downstream compo-
nents, might be more beneficial owing to
reduced off-target effects. In fact, such in-
hibitors, e.g., rapamycin and its ana-
logues RAD001 and sirolimus, were
found to be orally tolerated in a range of
studies targeting solid tumors. Recently
however, phase I clinical trials of tem-
sirolimus have been initiated in cotreat-
ment regimens for MM that involve
dexa methasone, Bortezomib or Lenalido-
mide (39). Based on our data, the use of
mTOR inhibitors might be further en-
hanced by cotreatment with specific
ERK1/2 inhibitors. An oral small mole-
cule MEK/ERK inhibitor, AZD6244, has
entered phase I/II clinincal trials in pa-
tients with solid tumors, and, based on
our results, may be beneficial in MM
 patients (40).
We propose that therapeutic ap-
proaches to treat MM could use two dif-
ferent regimens. One regimen employs
inhibitors against multiple targets in MM
PC (for example, MAPK and mTOR), or
uses an approach in which deregulated
kinases in both MM cells and their
stroma are targeted. With the second ap-
proach deregulated growth of MM cells
is counteracted via direct inhibition and
through a less favorable environment
(poisoning both the seed and soil to
eradicate tumor cells). In conclusion, our
findings show that phosphoproteome de-
termination is a valuable tool to generate
a global view of kinases deregulated in
MM and to provide putative targets for
treatment.
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